Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

(2016) Andrea Wang-Gillam et al.   LANCET

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

(2016) Mustafa Suker et al.   LANCET ONCOLOGY

Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice

(2015) Huan Meng et al.   ACS Nano

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours

(2015) B. Venugopal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein

(2015) J. J. Kamphorst et al.   CANCER RESEARCH

Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts

(2015) J. W. Cassidy et al.   CANCER RESEARCH

Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer

(2015) Robert M Hoffman et al.   EXPERT OPINION ON PHARMACOTHERAPY

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

(2015) Daniel V.T. Catenacci et al.   JOURNAL OF CLINICAL ONCOLOGY

Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy

(2015) Marina A. Dobrovolskaia   JOURNAL OF CONTROLLED RELEASE

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment

(2015) Ken Ohmine et al.   MOLECULAR PHARMACEUTICS

Nanoformulations for therapy of pancreatic and liver cancers

(2015) Patricia Coutinho de Souza et al.   Nanomedicine

Design considerations for nanotherapeutics in oncology

(2015) Triantafyllos Stylianopoulos et al.   Nanomedicine-Nanotechnology Biology and Medicine

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

(2015) Xiaofeng Zheng et al.   NATURE

Transcriptional control of autophagy–lysosome function drives pancreatic cancer metabolism

(2015) Rushika M. Perera et al.   NATURE

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

(2015) Ignacio Garrido-Laguna et al.   Nature Reviews Clinical Oncology

Clinical experiences with systemically administered siRNA-based therapeutics in cancer

(2015) Jonathan E. Zuckerman et al.   NATURE REVIEWS DRUG DISCOVERY

Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy

(2015) Christina H. Eng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Unraveling the complexity of autophagy: Potential therapeutic applications in Pancreatic Ductal Adenocarcinoma

(2015) Valentina E. Gómez et al.   SEMINARS IN CANCER BIOLOGY

The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy

(2015) Katherine M. Bever et al.   HPB

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

(2015) Agnieszka K. Witkiewicz et al.   Nature Communications

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

(2015) Talia Golan et al.   Oncotarget

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Abstract CT210: A phase 1 study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, administered to patients with refractory solid tumors on a weekly schedule

(2015) Monica Mita et al.   CANCER RESEARCH

Lessons from patient-derived xenografts for better in vitro modeling of human cancer

(2014) Stephen Yiu Chuen Choi et al.   ADVANCED DRUG DELIVERY REVIEWS

O-0003 * NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY

(2014) D. Von Hoff et al.   ANNALS OF ONCOLOGY

Combined MTOR and autophagy inhibition

(2014) Reshma Rangwala et al.   Autophagy

Humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles, an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity

(2014) Yin Xiangbao et al.   BIOMEDICINE & PHARMACOTHERAPY

Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis

(2014) Gillian K Gresham et al.   BMC CANCER

Compression of Pancreatic Tumor Blood Vessels by Hyaluronan Is Caused by Solid Stress and Not Interstitial Fluid Pressure

(2014) Vikash P. Chauhan et al.   CANCER CELL

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

(2014) Berna C. Özdemir et al.   CANCER CELL

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

(2014) Andrew D. Rhim et al.   CANCER CELL

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors

(2014) Devalingam Mahalingam et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genetic Progression of Pancreatic Cancer

(2014) Robert W. Cowan et al.   CANCER JOURNAL

Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion

(2014) A. V. Kalra et al.   CANCER RESEARCH

Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs

(2014) Daisuke Hashimoto et al.   EUROPEAN JOURNAL OF CANCER

Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

(2014) Lucas de Sousa Cavalcante et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Transport properties of pancreatic cancer describe gemcitabine delivery and response

(2014) Eugene J. Koay et al.   JOURNAL OF CLINICAL INVESTIGATION

First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors

(2014) Beate Schultheis et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and pharmacodynamics ofnab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel

(2014) Nianhang Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor

(2014) Sabrina Valetti et al.   JOURNAL OF CONTROLLED RELEASE

Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation

(2014) H.-Q. Ju et al.   MOLECULAR CANCER THERAPEUTICS

The clinical development of MEK inhibitors

(2014) Yujie Zhao et al.   Nature Reviews Clinical Oncology

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma

(2014) B. M. Wolpin et al.   ONCOLOGIST

Human Equilibrative Nucleoside Transporter-1 Knockdown Tunes Cellular Mechanics through Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells

(2014) Yeonju Lee et al.   PLoS One

Stromal response to Hedgehog signaling restrains pancreatic cancer progression

(2014) J. J. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer

(2014) Hideya Onishi   WORLD JOURNAL OF GASTROENTEROLOGY

Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies

(2014) Agnieszka Anna Rucki   WORLD JOURNAL OF GASTROENTEROLOGY

nab-Paclitaxel: Novel Clinical and Experimental Evidence in Pancreatic Cancer

(2014) A. Neesse et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations

(2014) A. Yang et al.   Cancer Discovery

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

Theranostic Nanoparticles with Controlled Release of Gemcitabine for Targeted Therapy and MRI of Pancreatic Cancer

(2013) Gee Young Lee et al.   ACS Nano

Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models

(2013) Pavan P. Adiseshaiah et al.   CANCER LETTERS

Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells

(2013) S. Maya et al.   CARBOHYDRATE POLYMERS

The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer

(2013) W. W. Ma et al.   CLINICAL CANCER RESEARCH

Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing® for efficient antitumor activity

(2013) Lucía Martín-Banderas et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

New cast for a new era: preclinical cancer drug development revisited

(2013) Grit S. Herter-Sprie et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

(2013) Elizabeth Poplin et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors

(2013) F.E. Stuurman et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

(2013) William Greenhalf et al.   JNCI-Journal of the National Cancer Institute

Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer

(2013) Linjuan Zeng et al.   Nanomedicine-Nanotechnology Biology and Medicine

Strategies for advancing cancer nanomedicine

(2013) Vikash P. Chauhan et al.   NATURE MATERIALS

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecularly Targeted Therapies in Metastatic Pancreatic Cancer

(2013) Flora Zagouri et al.   PANCREAS

Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis

(2013) Wei Tian et al.   PANCREATOLOGY

Mutant KRAS is a druggable target for pancreatic cancer

(2013) E. Zorde Khvalevsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combining two strategies to improve perfusion and drug delivery in solid tumors

(2013) T. Stylianopoulos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autophagy in tumour cell death

(2013) Robin L. Macintosh et al.   SEMINARS IN CANCER BIOLOGY

Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels

(2013) Vikash P. Chauhan et al.   Nature Communications

Pancreatic cancer: why is it so hard to treat?

(2013) Paul E. Oberstein et al.   Therapeutic Advances in Gastroenterology

Targeting Phosphoinositide 3-Kinase Pathways in Pancreatic Cancer – from Molecular Signalling to Clinical Trials

(2012) Marco Falasca et al.   Anti-Cancer Agents in Medicinal Chemistry

Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells

(2012) Anne-Laure Papa et al.   BMC CANCER

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

(2012) Paolo P. Provenzano et al.   CANCER CELL

A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies

(2012) John F. Deeken et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells

(2012) Prachi Joshi et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

(2012) Michael A Jacobetz et al.   GUT

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

(2012) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner

(2012) Vikash P. Chauhan et al.   Nature Nanotechnology

Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity

(2012) Stephan T Stern et al.   Particle and Fibre Toxicology

Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

(2012) J. Hrkach et al.   Science Translational Medicine

Sonic Hedgehog in pancreatic cancer: From bench to bedside, then back to the bench

(2012) David E. Rosow et al.   SURGERY

PI3K-PKB/Akt Pathway

(2012) B. A. Hemmings et al.   Cold Spring Harbor Perspectives in Biology

nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer

(2012) Kristopher K. Frese et al.   Cancer Discovery

Pharmacokinetics, Pharmacodynamics, and Allometric Scaling of Chloroquine in a Murine Malaria Model

(2011) Brioni R. Moore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Gemcitabine-loaded innovative nanocarriers vs GEMZAR: Biodistribution, pharmacokinetic features andin vivoantitumor activity

(2011) Christian Celia et al.   Expert Opinion on Drug Delivery

Pancreatic cancers require autophagy for tumor growth

(2011) S. Yang et al.   GENES & DEVELOPMENT

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

(2011) J. Y. Guo et al.   GENES & DEVELOPMENT

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

AACR Highlights: Promise for Treating Pancreatic Cancer

(2011) S. Jenks   JNCI-Journal of the National Cancer Institute

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

(2011) Gregory J. Riely et al.   Journal of Thoracic Oncology

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

(2011) S. T. Kim et al.   MOLECULAR CANCER THERAPEUTICS

A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothened Antagonists

(2011) V. Chenna et al.   MOLECULAR CANCER THERAPEUTICS

Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer

(2011) Soukaina Réjiba et al.   Nanomedicine-Nanotechnology Biology and Medicine

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size

(2011) H. Cabral et al.   Nature Nanotechnology

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatic Cancer: The Role of Pancreatic Stellate Cells in Tumor Progression

(2011) Siri Dunér et al.   PANCREATOLOGY

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

(2011) B. Diop-Frimpong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma

(2011) Jill E. Shea et al.   HPB

Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery

(2010) Jing Li et al.   AAPS Journal

Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma

(2010) Vittorio Gebbia et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Modulators of the hedgehog signaling pathway

(2010) Philipp Heretsch et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Diffusion of Particles in the Extracellular Matrix: The Effect of Repulsive Electrostatic Interactions

(2010) Triantafyllos Stylianopoulos et al.   BIOPHYSICAL JOURNAL

Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

(2010) Y Nakai et al.   BRITISH JOURNAL OF CANCER

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Delivering nanomedicine to solid tumors

(2010) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Gemcitabine Induces the VMP1 -Mediated Autophagy Pathway to Promote Apoptotic Death in Human Pancreatic Cancer Cells

(2010) Romina Pardo et al.   PANCREATOLOGY

Regulation of Mammalian Autophagy in Physiology and Pathophysiology

(2010) Brinda Ravikumar et al.   PHYSIOLOGICAL REVIEWS

Combinatorial Drug Conjugation Enables Nanoparticle Dual-Drug Delivery

(2010) Santosh Aryal et al.   Small

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions

(2010) Jennifer L. Spratlin et al.   Cancers

Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer

(2009) Chitta Ranjan Patra et al.   ADVANCED DRUG DELIVERY REVIEWS

Selective Filtering of Particles by the Extracellular Matrix: An Electrostatic Bandpass

(2009) Oliver Lieleg et al.   BIOPHYSICAL JOURNAL

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

(2009) C Yoo et al.   BRITISH JOURNAL OF CANCER

Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors

(2009) Kazuki N. Sugahara et al.   CANCER CELL

Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer

(2009) Muhammad W. Saif et al.   CANCER INVESTIGATION

The Double-Edged Sword of Autophagy Modulation in Cancer

(2009) E. White et al.   CLINICAL CANCER RESEARCH

Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411

(2009) Christopher H. Crane et al.   JOURNAL OF CLINICAL ONCOLOGY

Small-molecule modulators of the Sonic Hedgehog signaling pathway

(2009) Benjamin Z. Stanton et al.   Molecular BioSystems

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Nanomaterial standards for efficacy and toxicity assessment

(2009) Pavan P. Adiseshaiah et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Nanoparticle therapeutics: a personal perspective

(2009) Scott E. McNeil   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor

(2008) Yohei Saito et al.   CANCER SCIENCE

Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-β receptor inhibitor on extravasation of nanoparticles from neovasculature

(2008) Mitsunobu R. Kano et al.   CANCER SCIENCE

Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

(2008) James J. Farrell et al.   GASTROENTEROLOGY

The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells

(2008) Joe W. Ramos   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside

(2008) Toru Furukawa   JOURNAL OF GASTROENTEROLOGY